Glenmark Pharma Slips 3% On Observations Issued By USFDA For Baddi Plant - Dollar Advisory & Financial Services

Breaking

Tuesday 28 November 2017

Glenmark Pharma Slips 3% On Observations Issued By USFDA For Baddi Plant

Shares of Glenmark Pharma tumbled 3 percent in the early trade Tuesday on the back of observations issued by USFDA.

The US Food and Drug Administration has issued 7 observations to company's Baddi units as the company has failed to thoroughly review any unexplained discrepancy and also failure of a batch.

The observations includes, lack of written procedures for production & process controls and complaint records are deficient.

For more information Call us ✆ +91 9111-179961 or Visit Dollar Advisory

No comments:

Post a Comment